New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 10, 2012
04:20 EDTAAPL, APU, ZNGA, NILE, ATML, INTC, EOG, SMG, LULU, CELG, AGN, ROST, CMG, SBUX, WWEJim Cramer's "Mad Money"
Jim Cramer said that if investors really want to sell, they should take a deep breath and wait, but even more prudent would be to do a little buying.He explained that selling into a panic is often the worst time to sell. Cramer recalled the seven great American growth stocks he featured in April, stocks that included Apple (AAPL), Starbucks (SBUX), Chipotle Mexican Grill (CMG), Ross Stores (ROST), Allergan (AGN), Celgene (CELG) and Lululemon Athletica (LULU). All of these names, he said, are the perfect stocks to revisit after this week's market pullback. In all seven cases, Cramer said that these companies have superior growth, excellent management and long-term trends that transcend the market's short-term volatility. He said, the smart move would be to wait for the markets to take these great names lower and scoop them up while they're on sale. EXECUTIVE DECISION: Cramer sat down with Jim Hagedorn, chairman and CEO of Scotts Miracle-Gro (SMG), a stock that was hammered down 16% in Tuesday's trading after the company delivered a mixed quarter with a 9c earnings beat on lighter-than-expected revenue. Scotts currently yields 2.55%. Hagedorn said the company is meeting all of its internal expectations and is growing sales and taking share, but it simply couldn't meet the inflated expectations that the analysts had cooked up. Cramer remained bullish on Scotts after what was undoubtedly a strong quarter that was totally misunderstood by Wall Street. Then, Cramer once again spoke with Mark Papa, chairman and CEO of EOG Resources (EOG), an oil shale driller that posted a 3c earnings beat on a 47% yoy rise in revenue and a 49% increase in oil production. Papa explained that unlike other oil drillers, EOG is growing organically "through the drill bit" and is offering investors a higher rate of return by doing so. Cramer continued his support of EOG Resources. NO HUDDLE OFFENSE: Cramer said when it comes to secure stocks to own in 2012, both AT&T and Verizon offer growth, expanding gross margins and most importantly, no exposure to the chaos in Europe. LIGHTNING ROUND: (Bullish) INTC. (Bearish) ATML; NILE; ZNGA; APU; WWE. Reference Link
News For AAPL;SBUX;CMG;ROST;AGN;CELG;LULU;SMG;EOG;INTC;ATML;NILE;ZNGA;APU;WWE From The Last 14 Days
Check below for free stories on AAPL;SBUX;CMG;ROST;AGN;CELG;LULU;SMG;EOG;INTC;ATML;NILE;ZNGA;APU;WWE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
August 20, 2014
07:19 EDTAGNPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:07 EDTAGNSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
07:04 EDTAGNSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
06:28 EDTAAPLApple could delay iWatch until 2015, FT Alphaville reports
Subscribe for More Information
August 19, 2014
17:14 EDTAAPL, AGNOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTAGNAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
16:00 EDTAAPLOptions Update; August 19, 2014eBay
iPath S&P 500 VIX Short-Term Futures down 28c to 27.52. Option volume leaders: AAPL C HD PBR GILD AA NFLX TWTR TSLA EBAY according to Track Data.
14:40 EDTAGNSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
14:19 EDTAAPLCarl Icahn says increased Apple position over past year
Carl Icahn tweeted in regards to Apple, "All my chips still on the table and in fact increased position over past year." Icahn added that anyone who invested in Apple last year when he recommended the stock would be up 53% including dividends.
13:54 EDTAAPLCarney a contender to take over top communications job at Apple, Re/code says
Subscribe for More Information
13:13 EDTAGNAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTAGNSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTAGNAllergan approached Salix about takeover, WSJ reports
12:40 EDTAAPLApple nears life high, levels to watch
Subscribe for More Information
12:27 EDTAAPLIcahn says 'very sizable' shareholder of Apple, has not sold share
Subscribe for More Information
11:57 EDTAAPLApple shares reach $100, up 84c or 1%
09:38 EDTCELG, AAPLActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GILD TSLA CELG VLO VZ FB HD
07:33 EDTCELGCelgene announces publication of REVLIMID combination results
Celgene announced that results of a study evaluating the combination of REVLIMID with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone in untreated diffuse large b-cell lymphoma were published online ahead of print in the Journal of Clinical Oncology. In a phase II, open label, single arm study, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival with secondary endpoints of progression free survival and overall survival. A one-stage binomial design was used to assess the efficacy and tolerability of REVLIMID with R-CHOP. Of the 64 patients enrolled, 60 were eligible for response evaluation. In these patients, the overall response rate was 98% with 80% achieving a complete response. The 24-month EFS, which was identical to PFS, and OS rates were 59% and 78%, respectively. The company said, "This study demonstrated that the addition of lenalidomide to conventional R-CHOP resulted in similar PFS rates and OS rates between sub-types. This is intriguing as patients with the non-GCB phenotype have traditionally experienced poorer outcomes. The results of this study support further evaluation of this regimen in this sub-type of DLBCL.
06:32 EDTAAPLMorgan Stanley recommends adding to Apple positions
Subscribe for More Information
05:52 EDTZNGAStocks with implied volatility movement; GTAT ZNGA
Stocks with implied volatility movement; GT Advanced (GTAT) 76, Zynga (ZNGA) 52 according to iVolatility.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use